AQ4 is found in 2 entries

AQ4 as free ligands, exist in 2 entries. Examples include 1M17, 4HJO,

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Identifiers N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
Formula C22 H23 N3 O4
Molecular Weight 393.44 g/mol
Type non-polymer
Isomeric SMILES COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC
InChI InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)

Chemical Details

Formal Charge 0
Atom Count 52
Chiral Atom Count 0
Chiral Atoms
Bond Count 54
Aromatic Bond Count 17

Drug Info: DrugBank

DrugBank ID DB00530   (Stereoisomeric match)
Name Erlotinib
  • approved
  • investigational
Description Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
  • [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
  • Erlotinib
  • OSI-774
Salts Erlotinib Hydrochloride
Brand Names
  • Tarceva
  • Teva-erlotinib
Affected Organism Humans and other mammals
Indication For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Mechanism of action The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.
Route of administration oral
Categories Protein Kinase Inhibitors
ATC-Code L01XE03
AHFS-Code 10:00.00
CAS number 183321-74-6
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682